Welcome to our dedicated page for Aditxt SEC filings (Ticker: ADTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Aditxt, Inc. filings document the company’s life sciences platform, its common stock capital structure, and material events affecting its operating subsidiaries and public-company status. Recent Form 8-K reports cover the completed acquisition of Ignite Proteomics, related financial statements and pro forma information, senior unsecured promissory notes, at-the-market offering capacity, and Nasdaq listing-compliance matters.
Proxy materials and meeting reports describe board elections, auditor ratification, executive-compensation votes, reverse stock split authority, and other stockholder matters. The filing record also includes disclosures on preferred stock issued in acquisition consideration, equity financing arrangements, governance approvals, and risks associated with maintaining exchange listing standards.
Aditxt, Inc. reported the immediate resignations of two key leaders. On June 2, 2026, Christopher J. Porcelli resigned as General Counsel, Chief People Officer and Corporate Secretary, and the Board accepted his resignation the same day. Also on June 2, 2026, Brian Brady resigned as non-executive Chairman of the Board and as a director, effective immediately. The company states that Mr. Brady’s resignation was not due to any disagreement regarding operations, policies, or practices, although he had been chair of the Audit Committee and a member of both the Compensation and Nominating and Corporate Governance Committees.
Aditxt, Inc. announced a major leadership transition, with co-founder Amro Albanna resigning as Chief Executive Officer and director and Rowena Albanna resigning as Chief Operating Officer. Director Shahrokh Shabahang also resigned from the Board but remains Chief Innovation Officer.
The Board appointed Jeffrey M. Busch, age 68, as Interim Chief Executive Officer effective May 31, 2026, and named Brian Brady non-executive Chairman of the Board. Aditxt plans an interim employment arrangement for Mr. Busch that includes a $500,000 annual base salary, with full terms to be disclosed in a later filing.
The company highlighted Mr. Busch’s prior experience founding and leading Global Medical REIT to over $1 billion in enterprise value with an average 8.5% dividend yield, and stated that Aditxt does not currently have a dividend policy or plans to pay dividends.
Aditxt, Inc. reports that Nasdaq has notified the company it no longer meets key continued listing standards. Based on its Form 10-Q for the period ended March 31, 2026, the company reported stockholders’ equity of $(35,174,386), far below Nasdaq’s $2,500,000 minimum stockholders’ equity requirement.
The company already faces a prior delisting determination for failing the minimum bid price rule, with a Nasdaq Hearings Panel session set for June 11, 2026. Aditxt has also determined it is out of compliance with the $1,000,000 Market Value of Publicly Held Shares requirement. The company cautions that potential delisting and limited access to capital raise substantial doubt about its ability to continue as a going concern and could ultimately force it to discontinue operations.
Aditxt, Inc. is asking stockholders to approve a proposal that would permit the board to effect one or more reverse stock splits of common stock at ratios between 1-for-[●]1-for-[●][●], 2027. The proposal would also give the board discretion over the treatment of fractional shares, including paying cash or rounding up to the next whole share.
The board frames the proposal as a step to regain compliance with Nasdaq Listing Rule 5550(a)(2) (the $1.00 minimum bid requirement) and to permit the board flexibility to set the exact ratio and timing; stockholder approval would permit, but not require, the board to implement the Reverse Stock Split.
Aditxt, Inc. reported minimal Q1 2026 revenue of $12,159 from sales while operating expenses of $4.36M drove a net operating loss of $4.36M. A large non-cash loss from a jump in derivative liabilities lifted total net loss to $16.19M.
Cash fell to $268,852 at March 31, 2026 after $4.58M was used in operating activities, leaving a stockholders’ equity deficit of $35.17M. Management states there is substantial doubt about the company’s ability to continue as a going concern and is relying on new financings, including recent high-cost notes and preferred stock, to fund operations.
Aditxt, Inc. is implementing a 1-for-27 reverse stock split of its common stock to address Nasdaq’s minimum bid price requirement. The split becomes effective at 4:01 p.m. Eastern Time on May 15, 2026, with split-adjusted trading on Nasdaq beginning May 18, 2026 under the symbol ADTX.
Each 27 issued and outstanding shares will be combined into 1 share, with fractional shares rounded up. Authorized share count and par value remain unchanged, and stock options, restricted stock units, warrants, and plan reserves will be proportionally adjusted. Shares outstanding are expected to move from approximately 13,773,321 to approximately 510,123.
Aditxt, Inc. filed a Notification of Late Filing under Rule 12b-25 for the Form 10-Q covering the period ended March 31, 2026. The company cites time constraints in compiling and reviewing the quarter and states it will file the Form 10-Q no later than five calendar days after the original due date. The notification is signed by CEO Amro Albanna and dated May 15, 2026.
Aditxt, Inc. reported that Nasdaq staff has determined to delist its securities from The Nasdaq Capital Market after the company’s bid price stayed below $1.00 for 30 consecutive business days from March 24, 2026 through May 5, 2026, violating Nasdaq Listing Rule 5550(a)(2).
The company is not eligible for the usual 180‑day grace period because it has carried out reverse stock splits over the prior two years with a cumulative ratio of at least 250‑to‑1. Aditxt plans to request a hearing before a Nasdaq Hearings Panel, which will temporarily stay further delisting actions while it presents a plan to regain compliance. The company cautions there is no assurance the appeal or efforts to regain compliance will succeed.
Aditxt, Inc. held its 2026 virtual annual stockholder meeting with 294,398 common shares represented, equal to 34.17% of shares outstanding as of March 26, 2026, establishing a quorum. Stockholders elected five directors, each to serve until the 2027 annual meeting.
They ratified dbbmckennon as independent registered public accounting firm for the year ending December 31, 2026, and approved, on an advisory basis, the compensation of named executive officers. Stockholders also provided advisory input on how often to hold future executive pay votes.
Importantly, stockholders granted the board discretionary authority to implement a reverse stock split of common stock at a ratio between 1-for-2 and up to 1-for-250 within one year of approval, and authorized potential adjournment of the meeting to solicit additional proxies if needed.
HRT Financial LP, a ten percent owner of Aditxt, Inc., reported open-market sales of Class A shares. It sold 29,404 shares at $0.28 per share on April 24, 2026 and 3,811 shares at $0.29 per share on April 23, 2026. After these transactions, HRT Financial LP directly held 88,377 Class A shares.